Celon Pharma (FRA:8RP) COGS-to-Revenue : 0.35 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Celon Pharma COGS-to-Revenue?

Celon Pharma's Cost of Goods Sold for the three months ended in Sep. 2024 was €4.11 Mil. Its Revenue for the three months ended in Sep. 2024 was €11.71 Mil.

Celon Pharma's COGS to Revenue for the three months ended in Sep. 2024 was 0.35.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Celon Pharma's Gross Margin % for the three months ended in Sep. 2024 was 64.95%.

Celon Pharma COGS-to-Revenue Historical Data

The historical data trend for Celon Pharma's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celon Pharma COGS-to-Revenue Chart

Celon Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.23

0.27

0.36

0.41

Celon Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
COGS-to-Revenue	Get a 7-Day Free Trial															0.38	0.39	0.38	0.32	0.35

Celon Pharma COGS-to-Revenue Calculation

Celon Pharma's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	15.424	/	37.948
	=	0.41

Celon Pharma's COGS to Revenue for the quarter that ended in Sep. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	4.106	/	11.714
	=	0.35

Celon Pharma (FRA:8RP) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Celon Pharma's Gross Margin % for the three months ended in Sep. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	4.106 / 11.714
	=	64.95 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Celon Pharma COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Celon Pharma's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Celon Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celon Pharma SA (FRA:8RP) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

CLN:Poland

Address

Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092

Website

http://www.celonpharma.com

Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.

Celon Pharma Headlines

No Headlines